Cancer Biology & Medicine: 23 (6)

June 15, 2026; Volume 23,Issue 6

Editorial

Open Access
From overtreatment to precision: a new clinical standard for DCIS management
Schlomo Schneebaum

Cancer Biology & Medicine June 2026, 23 (6) 785-787; DOI: https://doi.org/10.20892/j.issn.2095-3941.2026.0010

Open Access
Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives
Jing Yu, Maochen Li, Yuhan Zhu, Shengnan Wang, Yuzhao Jiang, Wei Cui and Lingying Wu

Cancer Biology & Medicine June 2026, 23 (6) 788-795; DOI: https://doi.org/10.20892/j.issn.2095-3941.2026.0102

Open Access
Chinese expert consensus on additional surgery following endoscopic resection for early colorectal cancer (2025 edition)
Zhipeng Qi, Fuqiang Zhao, Xuhua Hu, Yunshi Zhong, Qian Liu, Zhongtao Zhang, Guiying Wang and Digestive Tract Polyp and Precancerous Lesion Professional Committee, China Anti-Cancer Association Colorectal Surgery Group, Society of Surgery, Chinese Medical Association Colorectal Group, Society of Digestive Endoscopy, Chinese Medical Association Surgical Group, Colorectal Tumor Committee, Chinese Medical Doctor Association

Cancer Biology & Medicine June 2026, 23 (6) 796-809; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0784

Open Access
Metabolic regulation of tumor-associated macrophage function and immunotherapy in cancer
Mingyue Zhao, Rui Chen and Ping Gao

Cancer Biology & Medicine June 2026, 23 (6) 810-832; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0626
Open Access
Drug resistance to antibody-drug conjugates: mechanisms, challenges, and perspectives
Yajing Liu, Yuwei Liu, Tingting Wu, Xiaoming Bai, Shuman Wang, Luyun Zhang, Zhiwen Fu and Chen Shi

Cancer Biology & Medicine June 2026, 23 (6) 833-864; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0707
Open Access
Opportunities and challenges of immunotherapy for patients with resectable and potentially resectable stage III non-small cell lung cancer
Yuzhen Cui, Jingdong Xu, Junxu Wen, Jianfeng Peng, Jiangao Ren, Ailing Liu, Xiangjiao Meng, Zhaoqin Huang and Anwen Liu

Cancer Biology & Medicine June 2026, 23 (6) 865-887; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0589

Open Access
HBx-mediated GPT2 suppression promotes liver cancer development by downregulating ADH1A
Hongjuan You, Xing Wang, Ruyu Liu, Yuxin Wang, Huanyang Zhang, Lihong Ma, Ensi Bao, Yujie Zhong, Xiangye Liu, Delong Kong, Xiucheng Pan, Xiaocui Li, Suping Qin, Kuiyang Zheng, Chen Li, Renxian Tang and Fanyun Kong

Cancer Biology & Medicine June 2026, 23 (6) 888-909; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0236
Open Access
Expansion of IL-2-independent tumor-infiltrating lymphocytes through a feeder-free process: a preclinical study for solid tumors
Ying Zhang, Sicheng Du, Rongrui Liu, Chuanhua Zhao, Juan Li, Sisi Ye, Man Zhang, Xingming Ma, Zhou He, Wenjia Zhuang, Huajun Jin and Jianming Xu

Cancer Biology & Medicine June 2026, 23 (6) 910-924; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0441
Open Access
Cancer-immunity cycle-based molecular subtypes in breast cancer predict the response to immune checkpoint inhibitors
Di Shao, Tianjian Yu, Yi Xiao and Zhiming Shao

Cancer Biology & Medicine June 2026, 23 (6) 925-945; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0611

Open Access
Sequential nimotuzumab plus gemcitabine and nab-paclitaxel chemotherapy followed by irreversible electroporation in advanced pancreatic ductal adenocarcinoma: a retrospective real-world analysis
Yang Liu, Dandan Wu, Xing Li, Xihao Zhang, Rentao Li, Yanmei Ou, Hao Wang, Tongguo Si, Rui Xia, Yong Xu, Huikai Li, Chuntao Gao and Jihui Hao

Cancer Biology & Medicine June 2026, 23 (6) 946-950; DOI: https://doi.org/10.20892/j.issn.2095-3941.2025.0848